MAPT and early-onset autosomal dominant Alzheimer disease: The NLRP3-ASC inflammasome, a critical sensor of innate immunity, presents a promising therapeutic target for addressing key pathogenic processes in Alzheimer’s disease, including prion-like Tau pathology seeding, amyloid pathology, and neuroinflammation (11).